Answers are grounded in this paper and cite their sources.
The LDL-C-lowering and attenuated atherosclerosis in animal models and reduced LDL-C in hypercholesterolemic patients has validated ACLY inhibition as a therapeutic strategy. Positive results from phase 3 long-term cardiovascular outcome trials in high-risk patients are required for bempedoic acid to be approved for prevention of atherosclerosis.
No takes yet. Share an insight, caveat, or question.
Burke et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: